Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia

INTRODUCTION: Anti-vascular endothelial growth factor therapy is the standard of care for neovascular age-related macular degeneration (nAMD). The dosage of two licensed agents, ranibizumab and aflibercept, was established through clinical trials; however, it is unclear if either agent is administer...

Descripción completa

Detalles Bibliográficos
Autores principales: Skelly, Adrian, Carius, Hans-Joachim, Bezlyak, Vladimir, Chen, Fred K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709459/
https://www.ncbi.nlm.nih.gov/pubmed/29164480
http://dx.doi.org/10.1007/s12325-017-0624-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709459/
https://www.ncbi.nlm.nih.gov/pubmed/29164480
http://dx.doi.org/10.1007/s12325-017-0624-6

Ejemplares similares